Program in Cellular and Molecular Biology, University of Michigan, Ann Arbor, MI 48109, United States.
Arch Biochem Biophys. 2013 Jul 1;535(1):49-55. doi: 10.1016/j.abb.2012.12.021. Epub 2013 Jan 11.
Phosphorylation of cardiac troponin I serines 43/45 (cTnISer43/45) by protein kinase C (PKC) is associated with cardiac dysfunction and yet there is disagreement about the role this cluster plays in modulating contractile performance. The present study evaluates the impact of phospho-null Ala substitutions at Ser43/45 (cTnISer43/45Ala) on contractile performance in intact myocytes. Viral-based gene transfer of cardiac troponin I (cTnI) or cTnISer43/45Ala resulted in time-dependent increases in expression, with 70-80% of endogenous cTnI replaced within 4days. Western analysis of intact and permeabilized myocytes along with immunohistochemistry showed each exogenous cTnI was incorporated into the sarcomere of myocytes. In contractile function studies, there were no differences in shortening and re-lengthening for cTnI and cTnISer43/45Ala-expressing myocytes 2days after gene transfer. However, more extensive replacement with cTnISer43/45Ala after 4days diminished peak shortening amplitude and accelerated re-lengthening measured as the time to 50% re-lengthening (TTR50%). A decrease in myofilament Ca(2+) sensitivity of tension also was observed in permeabilized myocytes expressing cTnISer43/45Ala and is consistent with accelerated re-lengthening observed in intact myocytes under basal conditions. Phosphorylation of cTnI Ser23/24 and the Ca(2+) transient were not changed in these myocytes. These results demonstrate extensive sarcomere expression of cTnISer43/45Ala directly modulates myofilament function under basal conditions. In further work, the accelerated re-lengthening observed in control or cTnI-expressing myocytes treated with the PKC agonist, endothelin-1 (ET, 10nM) was slowed in myocytes expressing cTnISer43/45Ala. This outcome may indicate Ser43/45 is targeted for phosphorylation by ET-activated PKC and/or influences transduction of this agonist-activated response.
心肌钙蛋白 I 丝氨酸 43/45 位(cTnISer43/45)的蛋白激酶 C(PKC)磷酸化与心脏功能障碍有关,但对于该簇在调节收缩性能中的作用存在争议。本研究评估了在完整心肌细胞中磷酸化缺失的丙氨酸取代 cTnISer43/45(cTnISer43/45Ala)对收缩性能的影响。基于病毒的心肌钙蛋白 I(cTnI)或 cTnISer43/45Ala 的基因转移导致表达的时间依赖性增加,在 4 天内有 70-80%的内源性 cTnI 被取代。完整和透化的心肌细胞的 Western 分析以及免疫组织化学显示,每种外源性 cTnI 都被整合到肌节中。在收缩功能研究中,在基因转移后 2 天,cTnI 和 cTnISer43/45Ala 表达的心肌细胞的缩短和再延长没有差异。然而,在 4 天后用 cTnISer43/45Ala 进行更广泛的替换会降低峰值缩短幅度并加速再延长,以 50%再延长的时间(TTR50%)来衡量。在表达 cTnISer43/45Ala 的透化心肌细胞中也观察到肌丝 Ca2+敏感性张力的降低,这与在基础条件下完整心肌细胞中观察到的再延长加速一致。这些肌细胞中 cTnI Ser23/24 的磷酸化和 Ca2+瞬变没有改变。这些结果表明,在基础条件下,cTnISer43/45Ala 的广泛肌节表达直接调节肌丝功能。在进一步的工作中,在对照或用 PKC 激动剂内皮素-1(ET,10nM)处理的 cTnI 表达的心肌细胞中观察到的再延长加速在表达 cTnISer43/45Ala 的心肌细胞中减慢。这种结果可能表明 Ser43/45 是 ET 激活的 PKC 磷酸化的靶点,和/或影响这种激动剂激活反应的转导。